Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/29/23 | UPLOAD | SEC-generated letter |
|
1 | |
| 12/27/23 | 8-K | Current report filing |
|
   |
2 |
| 12/22/23 | S-3 | Registration statement for specified transactions by certain issuers |
|
137 | |
| 12/15/23 | 8-K | Current report filing |
|
|
2 |
| 12/14/23 | 8-K | Current report filing |
|
|
5 |
| 12/14/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
82 |
| 11/17/23 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 11/06/23 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 10/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
